Acetyl-l-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis

Psychosomatic Medicine

Volumn 80, Issue 2, 2018, Pages 154-159

  Veronese, Nicola ^a   Stubbs, Brendon ^b,c,d   Solmi, Marco ^e   Ajnakina, Olesya ^c   Carvalho, Andre F ^f   Maggi, Stefania ^a  

^a CNR   (Italy)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF PADOVA   (Italy)

^f FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

acetyl L carnitine; depression; meta analysis

Indexed keywords

ANTIDEPRESSANT AGENT; LEVACECARNINE; PLACEBO; ACETYLCARNITINE; VITAMIN B COMPLEX;

ADULT; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON DEPRESSION RATING SCALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; DIETARY SUPPLEMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACETYLCARNITINE; ANTIDEPRESSIVE AGENTS; DEPRESSION; DIETARY SUPPLEMENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN B COMPLEX;

EID: 85041724350     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0000000000000537     Document Type: Review

References (56)

1. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G,Murray CJ, Vos T, Whiteford HA. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013;10: e1001547.
2. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, Rosenbaum S, Gaughran F, Lally J, Stubbs B. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 2016;15:166-74.
3. VancampfortD,MitchellAJ, De Hert M, Sienaert P, Probst M, Buys R, Stubbs B. Type 2 diabetes in patients with major depressive disorder: a meta-analysis of prevalence estimates and predictors. Depress Anxiety 2015;32:763-73.
4. Cole MG, Dendukuri N. Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. Am J Psychiatry 2003;160:1147-56.
5. Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P, Saxena S. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry 2016;3:415-24.
6. Bruti G, Magnotti MC, Iannetti G. Migraine and depression: bidirectional comorbidities? Neurol Sci 2012;33(suppl 1):S107-9.
7. Bernik M, Sampaio TP, Gandarela L. Fibromyalgia comorbid with anxiety disorders and depression: combined medical and psychological treatment. Curr Pain Headache Rep 2013;17:358.
8. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998;43:315-9.
9. Jones LL, McDonald DA, Borum PR. Acylcarnitines: role in brain. Prog Lipid Res 2010;49:61-75.
10. Steiber A, Kerner J, Hoppel CL. Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med 2004;25:455-73.
11. Pettegrew JW, Levine J,McClure RJ. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 2000;5:616-32.
12. Di Cesare Mannelli L, Ghelardini C, Toscano A, Pacini A, Bartolini A. The neuropathy-protective agent acetyl-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain. Neuroscience 2010;165:1345-52.
13. Pettegrew JW, Levine J, Gershon S, Stanley JA, Servan-Schreiber D, Panchalingam K, McClure RJ. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord 2002;4:61-6.
14. Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. A review of current evidence for acetyl-L-carnitine in the treatment of depression. J Psychiatr Res 2014;53:30-7.
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1-34.
16. Stroup DF, Berlin JA,Morton SC, Olkin I,Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. JAMA 2000;283:2008-12.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62.
18. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
19. Jadad AR. The merits of measuring the quality of clinical trials: is it becoming a Byzantine discussion? Transpl Int 2009;22:1028.
20. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration 2008. Available at: https://dhosth. files. wordpress. com/2011/12/cochrane-handbook-for-systematic-reviews-of-interventions. pdf. Accessed April 20, 2016.
21. Egger M,Davey Smith G, SchneiderM,MinderC. Bias inmeta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
22. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63.
23. Bella R, Biondi R, Raffaele R, Pennisi G. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res 1990;10: 355-60.
24. Bersani G, Meco G, Denaro A, Liberati D, Colletti C, Nicolai R, Bersani FS, Koverech A. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol 2013;23:1219-25.
25. Fulgente T, OnofrjM, Del ReML, Ferracci F, Bazzano S, Ghilardi MF,Malatesta G. Laevo-acetylcarnitine (Nicetile®) treatment of senile depression. Clin Trials J 1990;27:155-63.
26. Garzya G, Corallo D, Fiore A, Lecciso G, Petrelli G, Zotti C. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990;16:101-6.
27. Gavrilova SI, Kalyn YB, Safarova TP, Yakovleva OB, Sheshenin VS, Kornilov VV, Shipilova ES. Optimization of the efficacy and safety of antidepressant therapy in patients of a geriatric psychiatric unit. Zh Nevrol Psikhiatr Im S S Korsakova 2015;115:24-32.
28. GeceleM, Francesetti G, Meluzzi A. Acetyl-L-carnitine in aged subjects with major depression: clinical efficacy and effects on the circadian rhythm of cortisol. Dementia 1991;2:333-7.
29. Hagen K, Brenner E, Linde M, Gravdahl GB, Tronvik EA, Engstrøm M, Sonnewald U, Helde G, Stovner LJ, Sand T. Acetyl-L-carnitine versus placebo for migraine prophylaxis: a randomized, triple-blind, crossover study. Cephalalgia 2015;35:987-95.
30. Leombruni P, Miniotti M, Colonna F, Sica C, Castelli L, Bruzzone M, Parisi S, Fusaro E, Sarzi-Puttini P, Atzeni F, Torta RG. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clin Exp Rheumatol 2015;33:S82-5.
31. Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP,Motta M, Mistretta A, Rampello L, Pennisi G. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol 2011;46:750-9.
32. Rossini M, Di Munno O, Valentini G, Bianchi G, Biasi G, Cacace E, Malesci D, La Montagna G,Viapiana O, Adami S. Double-blind, multicenter trial comparing acetyl L-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol 2007;25:182-8.
33. Tempesta E, Casella L, Pirrongelli C, Janiri L, Calvani M, Ancona L. L-Acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res 1987;13:417-23.
34. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol 2006;16:281-7.
35. Nasca D, Zurria G, Aguglia E. Action of acetyl-L-carnitine in association with mianserine on depressed old people. New Trends Clin Neuropharmacol 1989;3: 225-30.
36. Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, Fieschi C. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 2004;218:103-8.
37. Brennan BP, Jensen JE, Hudson JI, Coit CE, Beaulieu A, Pope HG Jr., Renshaw PF, Cohen BM. A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression. J Clin Psychopharmacol 2013;33:627-35.
38. Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 2004;63:641-6.
39. Martinotti G, Andreoli S, Reina D, Di Nicola M, Ortolani I, Tedeschi D, Fanella F, Pozzi G, Iannoni E, D'Iddio S, Prof LJ. Acetyl-L-carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:953-8.
40. Zanelli SA, Solenski NJ, Rosenthal RE, Fiskum G. Mechanisms of ischemic neuroprotection by acetyl-L-carnitine. Ann N YAcad Sci 2005;1053:153-61.
41. Chiappelli J, Rowland LM, Wijtenburg SA, Muellerklein F, Tagamets M, McMahon RP, Gaston F, Kochunov P, Hong LE. Evaluation of myo-inositol as a potential biomarker for depression in schizophrenia. Neuropsychopharmacology 2015;40:2157-64.
42. Nakamura J, Koh N, Sakakibara F, Hamada Y, Hara T, Sasaki H, Chaya S, Komori T, Nakashima E, Naruse K, Kato K, Takeuchi N, Kasuya Y, Hotta N. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats. J Pharmacol Exp Ther 1998;287:897-902.
43. Smeland OB, Meisingset TW, Borges K, Sonnewald U. Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice. Neurochem Int 2012;61:100-7.
44. Tolu P, Masi F, Leggio B, Scheggi S, Tagliamonte A, DeMontisMG,Gambarana C. Effects of long-term acetyl-L-carnitine administration in rats: I. Increased dopamine output in mesocorticolimbic areas and protection toward acute stress exposure. Neuropsychopharmacology 2002;27:410-20.
45. Li S, Li Q, Li Y, Li L, Tian H, Sun X. Acetyl-L-carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2015;10:e0119479.
46. Veronese N, Sergi G, Stubbs B, Bourdel-Marchasson I, Tessier D, Sieber C, Strandberg T, Gillain S, Barbagallo M, Crepaldi G, Maggi S, Manzato E. Effect of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy: a systematic review and meta-analysis. Eur Geriatr Med 2017;8:117-22.
47. Stubbs B, Koyanagi A, Thompson T, Veronese N, Carvalho AF, Solmi M, Mugisha J, Schofield P, Cosco T, Wilson N, Vancampfort D. The epidemiology of back pain and its relationship with depression, psychosis, anxiety, sleep disturbances, and stress sensitivity: data from 43 low-and middle-income countries. Gen Hosp Psychiatry 2016;43:63-70.
48. Stubbs B, Vancampfort D, Veronese N, Thompson T, Fornaro M, Schofield P, Solmi M, Mugisha J, Carvalho AF, Koyanagi A. Depression and pain: primary data and meta-analysis among 237 952 people across 47 low-and middleincome countries. Psychol Med 2017:1-12.
49. Thompson T, Correll CU, Gallop K, Vancampfort D, Stubbs B. Is pain perception altered in people with depression? A systematic review and meta-analysis of experimental pain research. J Pain 2016;17:1257-72.
50. Bair MJ, Robinson RL, KatonW, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433-45.
51. Gerrits MM, van Oppen P, van Marwijk HW, Penninx BW, van der Horst HE. Pain and the onset of depressive and anxiety disorders. Pain 2014;155:53-9.
52. Rico-Villademoros F, Slim M, Calandre EP. Amitriptyline for the treatment of fibromyalgia: a comprehensive review. Expert Rev Neurother 2015;15: 1123-50.
53. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
54. Cuijpers P, Turner EH, Koole SL, van Dijke A, Smit F. What is the threshold for a clinically relevant effect? The case of major depressive disorders. Depress Anxiety 2014;31:374-8.
55. Meister R, von Wolff A, Mohr H, Härter M, Nestoriuc Y, Holzel L, Kriston L. Comparative safety of pharmacologic treatments for persistent depressive disorder: a systematic review and network meta-analysis. PLoS One 2016;11: e0153380.
56. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551.